TRAW
Traws Pharma, Inc.Company Information
- Company Name
- Traws Pharma, Inc.
- CIK
- CIK0001130598
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- TRAW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- TRAW
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-04-16
- Last sale
- —
- Shares purchased (TTM)
- 597,729
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 6,038,125
- Shares outstanding
- 15,864,041
- Ownership
- 38.06%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -3.51%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 5 | 3 | 4 | 6 | 13 | 16 | 21 | 5 | 17 | 16 | 21 | 25 | ||||||
| Receivables Net Current | 3 | 2 | 4 | 2 | 1 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 2 | ||||||
| Assets Current | 9 | 6 | 8 | 10 | 15 | 19 | 25 | 9 | 19 | 18 | 23 | 27 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Finite Lived Intangible Assets Net | 2 | 2 | 3 | 3 | - | - | - | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 11 | 8 | 11 | 12 | 16 | 19 | 25 | 9 | 19 | 18 | 23 | 27 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 6 | 8 | 6 | 5 | 5 | 8 | 8 | 5 | 6 | 7 | 6 | 6 | ||||||
| Accrued Liabilities Current | 3 | 6 | 5 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 3 | ||||||
| Contract With Customer Liability Current | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 10 | 13 | 11 | 8 | 7 | 10 | 12 | 8 | 10 | 9 | 9 | 10 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | - | - | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Warrants And Rights Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 42 | - | - | - | - | - | ||||||
| Liabilities | 10 | 13 | 11 | 8 | 7 | 13 | 57 | 11 | 13 | 12 | 12 | 13 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | - | - | 112 | - | - | - | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 652 | 642 | 639 | 637 | 637 | 634 | 618 | 617 | 505 | 493 | 493 | 493 | ||||||
| Retained Earnings Accumulated Deficit | -650 | -647 | -640 | -633 | -629 | -628 | -649 | -619 | -611 | -488 | -483 | -478 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Stockholders Equity | 2 | -5 | -1 | 5 | 8 | 6 | -32 | -2 | -106 | 6 | 11 | 15 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | 0.01 | - | - | - | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | - | - | 5 | - | - | - | ||||||
| Temporary Equity Shares Issued | - | - | - | - | - | - | - | - | 0 | - | - | - | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | - | - | 0 | - | - | - | ||||||
| Liabilities And Stockholders Equity | 11 | 8 | 11 | 12 | 16 | 19 | 25 | 9 | 19 | 18 | 23 | 27 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | - | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | - | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 125 | 125 | 250 | 125 | ||||||
| Common Stock Shares Issued | 15 | 10 | 9 | 7 | 7 | 5 | 4 | 3 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 15 | 10 | 9 | 7 | 7 | 5 | 4 | 3 | 1 | 1 | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTraws Pharma, Inc. (TRAW) — SEC Financial Statements & Analysis
Traws Pharma, Inc. (TRAW) is a pharmaceutical preparations company, incorporated in DE. Traws Pharma, Inc. trades on Nasdaq as: TRAW. Traws Pharma, Inc. (TRAW)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Traws Pharma, Inc. carries a market cap of $13.33M, a P/E ratio of -0.63x, a P/B ratio of 7.88x, a P/S ratio of 4.78x, an enterprise value of $8.31M, and an EV/EBITDA multiple of -0.39x. On profitability, it posts an operating margin of -772.19%, a net margin of -757.10%, a Return on Equity (ROE) of -424.45%, and a Return on Assets (ROA) of -155.94%. Per share, it reports EPS of $-1.33, diluted EPS of $-1.33, free cash flow per share of $-1.23, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -7.49% year-over-year, net income growth of -82.43% year-over-year, and EPS growth of -93.55% year-over-year. On the balance sheet, it maintains a current ratio of 0.93x, a quick ratio of 0.87x, working capital of $-712.00K, a debt-to-equity ratio of 5.78x, a debt ratio of 0.85, free cash flow of $-19.43M (TTM), and net debt of $-5.02M. Figures sourced from SEC EDGAR.
- Market Cap
- $13.33M
- P/E TTM
- -0.63x
- EPS TTM
- $-1.33
- P/B TTM
- 7.88x
- ROE TTM
- -424.45%
- ROA TTM
- -155.94%
- Debt To Equity
- 5.78x
- Free Cash Flow TTM
- $-19.43M
- Net Revenue TTM Growth 1Y
- -7.49%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Traws Pharma, Inc. in?
Traws Pharma, Inc. (TRAW) operates in the Pharmaceutical Preparations industry.
What exchange does TRAW trade on?
Traws Pharma, Inc. (TRAW) trades on the Nasdaq.
Where is Traws Pharma, Inc. incorporated?
Traws Pharma, Inc. is incorporated in DE.
When was Traws Pharma, Inc. (TRAW)'s most recent SEC filing?
Traws Pharma, Inc. (TRAW)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is TRAW's market cap?
Traws Pharma, Inc. (TRAW) has a market capitalization of $13.33M as of 2026-06-30.
What is TRAW's EPS (earnings per share)?
Traws Pharma, Inc. (TRAW)'s trailing twelve month EPS is $-1.33 as of 2026-06-30.
What is TRAW's ROE (return on equity)?
Traws Pharma, Inc. (TRAW)'s trailing twelve month Return on Equity (ROE) is -424.45% as of 2026-06-30.
What is TRAW's ROA (return on assets)?
Traws Pharma, Inc. (TRAW)'s trailing twelve month Return on Assets (ROA) is -155.94% as of 2026-06-30.
What is TRAW's EV/EBITDA?
Traws Pharma, Inc. (TRAW)'s trailing twelve month EV/EBITDA is -0.39x as of 2026-06-30.